Tag: Cerapedics

cerapedics

Cerapedics announces expansion of Colorado headquarters

Cerapedics has announced the expansion of the company's headquarters located in the Denver metropolitan area. Over the past 18 months, Cerapedics has grown from...

ISASS bone grafting policy statement features i-FACTOR peptide enhanced bone graft

The International Society for the Advancement of Spine Surgery (ISASS) recently issued a new bone grafting policy that features i‑FACTOR peptide enhanced bone graft...
IDE

Cerapedics announces first patients enrolled in IDE clinical trial of P-15L...

  The first patients have been enrolled in an investigational device exemption (IDE) clinical trial evaluating the safety and efficacy of the next-generation P-15L peptide...
financing

Cerapedics announces closing of US$22 million financing

Cerapedics has announced that the company completed a US$22 million financing led by KCK Group, a family investment fund that focuses on innovative medical...
financing

Use of i-FACTOR peptide enhanced bone graft more than doubles fusion...

The use of i-FACTOR peptide enhanced bone graft (Cerapedics) resulted in a 50% fusion rate, compared to a 20% fusion rate using allograft in...

Cerapedics receives FDA approval to initiate IDE study of P-15L bone...

Cerapedics, a privately-held orthobiologics company, has announced the company received approval from the US Food and Drug Administration (FDA) to initiate an investigational device...
i-FACTOR bone graft Cerapedics

i-FACTOR™: Small peptide, big impact

This article is sponsored by Cerapedics, Inc. A FAST, RELIABLE AND PROVEN ALTERNATIVE TO AUTOGRAFT i-FACTOR peptide-enhanced bone graft is challenging the gold standard in bone...
I-factor peptide-enhanced bone graft

Peptide-enhanced bone graft outperforms autograft at two years

A prospective, multicentre trial has found that a peptide-enhanced bone graft is non-inferior compared to local autograft bone. In addition, the bone graft outperformed...

Two-year results show statistical superiority of Cerapedics’ I-Factor to autograft in...

Cerapedics has announced the publication of two-year follow-up data from a US Food and Drug Administration (FDA) Investigational Device Exemption (IDE) clinical trial of...

Cerapedics awarded group purchasing agreement with Premier for I-Factor

Cerapedics has been awarded a group purchasing agreement with Premier, a healthcare improvement company. The new agreement allows Premier members, at their discretion, to take...